Various Prothrombin Complex Concentrates and their Effect on Coagulation and Fibrinolysis In Vivo

U Hedner; I.M Nilsson; S.-E Bergentz

doi:10.1055/s-0038-1647933

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1976; 35(02): 386-395
DOI: 10.1055/s-0038-1647933

Original Article

Schattauer GmbH

Various Prothrombin Complex Concentrates and their Effect on Coagulation and Fibrinolysis In Vivo

Authors

U Hedner

¹Coagulation Laboratory, University of Lund, Allmänna Sjukhuset, Malmö, Sweden
I.M Nilsson

¹Coagulation Laboratory, University of Lund, Allmänna Sjukhuset, Malmö, Sweden
S.-E Bergentz

¹Coagulation Laboratory, University of Lund, Allmänna Sjukhuset, Malmö, Sweden

Abstract

Summary

Thromboembolic complications occurring in patients treated with factor IX concentrates have been reported. To study the thrombogenicity various types of factor IX concentrates (50 or 100 units F. IX/kg bodyweight) have been infused in dogs. As control albumin was given. The various components of the coagulation and fibrinolytic system have been assayed before the infusion and at various intervals after the end of infusion (0, 1,4 and 24 hrs). Konyne resulted in marked activation of the coagulation process with decrease of platelets, fibrinogen, F. VIII and appearance of FDP and positive ethanol gelation test. Pro thro mplex and Pre-conativ gave no significant changes. Preconativ is prepared without addition of heparin during the procedure.

Full Text

References

References
1 Biggs R. 1970. Clinical experience with factor IX concentrate of Bidwell. In: Brinkhous K. M. (Ed.). Hemophilia and New Hemorrhagic States, International Symposium, New York . The University of North Carolina Press; Chapel Hill: p 31.
2 Blatt P. M, Lundblad R. L, Kingdon H. S, McLean G, Roberts H. R. 1974; Thrombogenic materials in prothrombin complex concentrates. Annals of Internal Medicine 81: 766.
3 Breen Jr. F. A, Tullis J. L. 1969; Prothrombin concentrates in treatment of Christmas disease and allied disorders. The Journal of the American Medical Association 208: 1853.
4 Cash J. D, Dalton R. G, Middleton S, Smith J. K. 1975; Studies on the thrombogenicity of Scottish factor IX concentrates in dogs. Thrombosis et Diathesis Haemorrhagica (Stuttg.) 33: 632.
5 Cederbaum A. I, Roberts H. R. 1973; Complications of the use of prothrombin complex concentrates in liver disease. Clinical Research 21: 92.
6 Deyktn D, Wessler S. 1964; Activation product, factor IX, serum thrombotic accelerator activity, and serum-induced thrombosis. Journal of Clinical Investigation 43: 160.
7 Edson J. R. 1974; Prothrombin-complex concentrates and thrombosis. New England Journal of Medicine 290: 403.
8 Fagerhol M. K, Abildgaard U. 1970; Immunological studies on human antithrombin III. Influence of age, sex and use of oral contraceptives on serum concentration. Scandinavian Journal of Haematology 7: 10.
9 Ganrot P. O. 1966; Determination of α₂-macroglobulin as trypsinprotein esterase. Clinica Chimica Acta 14: 493.
10 Godal H. C, Abildgaard U, Kierulf P. 1971; Ethanol gelation and fibrin monomers in plasma. Scandinavian Journal of Haemotology, Suppl 13: 189.
11 Grammens G. L, Breckenridge R. T. 1974; Complications with Christmas factor (factor IX) concentrates. Annals of Internal Medicine 80: 666.
12 Kasper C. K. 1973; Postoperative thrombosis in hemophilia B. New England Journal of Medicine 289: 160.
13 Kasper C. K. 1975; Thromboembolic complications. Thrombosis et Diathesis Haemorrhagica (Stuttg.) 33: 640.
14 King J. B, Fitzgerald L. D. 1975 Platelet count in original plasma in relation to thrombogenicity of factor IX concentrate. XIV Congress of the International Society of Blood Transfusion, X Congress of the World Federation of Hemophilia, Helsinki, Finland July 27 - August 1. .
15 Kingdon H. S, Lundblad R. L, Veltkamp J. J, Aronson D. L. 1975; Potentially thrombogenic materials in factor IX concentrates. Thrombosis et Diathesis Haemorrhagica (Stuttg.) 33: 617.
16 Latallo Z. S, Wegrzynowicz E, Teisseyre E, Kopeć M. 1970; Simple and rapid evaluation of the intravascular coagulation and fibrinolytic status by application of protamine sulphate and Reptilase. Scandinavian Journal of Haematology, Suppl 13: 387.
17 Leandoer L, Bergentz S.-E, Nilsson I. M. 1968; Coagulation factors and components of the fibrinolytic system in lymph and blood in dogs. Thrombosis et Diathesis Haemorrhagica 19: 129.
18 Marchesi S. L, Burney R. 1974; Prothrombin-complex concentrates and thrombosis. New England Journal of Medicine 290: 403.
19 Ménaché D. 1975; Factor IX concentrates. Thrombosis et Diathesis Haemorrhagica (Stuttg.) 33: 600.
20 Ménaché D, Guillin M. C. 1975; The use of factor IX concentrates for patients with conditions other than factor IX deficiency. British Journal of Haemotology 31 (Suppl), 247.
21 Niléhn J.-E. 1967; Separation and estimation of “split products” of fibrinogen and fibrin in human serum. Thrombosis et Diathesis Haemorrhagica 18: 487.
22 Nilsson I. M. 1974. Haemorrhagic and Thrombotic Diseases. John Wiley & Sons; London:
23 Nilsson I. M, Ahlberg Å, Björlin G. 1971; Clinical experience with a Swedish factor IX concentrate. Acta medica scandinavica 190: 257.
24 Nilsson I. M, Blombäck M, Ramgren O. 1961; Haemophilia in Sweden. I. Coagulation studies. Acta medica scandinavica 170: 665.
25 Nilsson I. M, Olow B. 1962; Determination of fibrinogen and fibrinogenolytic activity. Thrombosis et Diathesis Haemorrhagica 8: 297.
26 Paraskevas M, Nilsson I. M, Martinsson G. 1962; A method for determining serum inhibitors of plasminogen activation. Scandinavian Journal of Clinical and Laboratory Investigation 14: 138.
27 Soulier J. P, Ménaché D, Steinbach M, Blatrix C. H, Josso F. 1969; Preparation and clinical use of P.P.S.B, (factors II, VII, X and IX concentrates). Thrombosis et Diathesis Haemorrhagica, Suppl 35: 61.
28 Steinberg M. H, Dreiling B. J. 1974; Vascular lesions in hemophilia B. New England Journal of Medicine 289: 592.
29 Tullis J. L, Melin M, Jurgian P. 1965; Clinical use of human prothrombin complexes. New England Journal of Medicine 273: 667.